CLINICAL PRACTICE GUIDELINES: Dupixent (dupilumab) Patient Selection
SOURCE: Joint Task Force Practice Parameter Update
PUBLICATION DATE: 09/2024
GUIDELINE VERSION: 2.0

I. DISEASE SEVERITY ASSESSMENT TOOLS

A. ATOPIC DERMATITIS SCORING
1. EASI (Eczema Area and Severity Index):
   - Mild: < 7
   - Moderate: 7-16
   - Severe: > 16
   - Treatment threshold: ≥ 16 for biologics

2. IGA (Investigator's Global Assessment):
   - 0 = Clear
   - 1 = Almost clear
   - 2 = Mild
   - 3 = Moderate (treatment threshold)
   - 4 = Severe

3. Pruritus NRS: 0-10 scale (significant if ≥ 4)

B. ASTHMA PHENOTYPE CRITERIA
1. Eosinophilic phenotype defined by:
   a. Adults (≥ 18 years): Blood eosinophils ≥ 300 cells/μL
   b. Adolescents (12-17 years): Blood eosinophils ≥ 150 cells/μL
   c. Children (6-11 years): Blood eosinophils ≥ 150 cells/μL OR FeNO ≥ 20 ppb

2. Alternative qualifying criteria:
   - Sputum eosinophils ≥ 2% (if available)
   - History of allergic asthma with total IgE > 100 IU/mL

C. CRSwNP ASSESSMENT
1. Nasal Polyp Score (NPS): 0-8 total (0-4 each nostril)
   - Treatment threshold: ≥ 5
2. SNOT-22 score: ≥ 30 indicates significant impact
3. Smell test: Anosmia or severe hyposmia

D. EoE DIAGNOSTIC CRITERIA
1. Peak eosinophil count:
   - ≥ 15 eosinophils per high-power field
   - In ≥ 1 biopsy from either proximal or distal esophagus
2. Dysphagia Symptom Questionnaire (DSQ) score ≥ 30

E. PRURIGO NODULARIS ASSESSMENT
1. Nodule count categories:
   - Mild: < 20 nodules
   - Moderate: 20-100 nodules
   - Severe: > 100 nodules
2. Pruritus NRS: Daily average ≥ 7 for one week
3. DLQI score > 10 indicates severe impact

II. PRIOR THERAPY SPECIFICATIONS

A. ATOPIC DERMATITIS
1. Topical corticosteroids:
   - Class I-II (super/high potency) for ≥ 4 weeks
   - OR Class III-IV with occlusion for ≥ 4 weeks
2. Topical calcineurin inhibitors:
   - Tacrolimus 0.1% BID for ≥ 6 weeks (adults)
   - Tacrolimus 0.03% BID for ≥ 6 weeks (children)
3. Systemic therapy (one required for severe):
   - Cyclosporine 3-5 mg/kg/day for ≥ 12 weeks
   - Methotrexate 15-25 mg/week for ≥ 12 weeks
   - Phototherapy: NB-UVB 3x/week for ≥ 12 weeks

B. ASTHMA
1. High-dose ICS/LABA definitions by age:
   - Adults: ≥ 500 mcg fluticasone propionate equivalent
   - Children 6-11: ≥ 200 mcg fluticasone propionate equivalent
2. Additional controllers tried for ≥ 3 months:
   - LAMA (tiotropium)
   - Leukotriene modifier
   - Theophylline (if appropriate)

C. CRSwNP
1. Intranasal corticosteroids: Maximum dose for ≥ 8 weeks
2. Systemic corticosteroids: ≥ 2 courses in past year
3. Saline irrigations: Daily for ≥ 4 weeks
4. Surgery consideration: If NPS ≥ 6 or prior surgery

D. EoE
1. PPI trial:
   - Adults: Omeprazole 40 mg BID for 8 weeks
   - Pediatrics: 1-2 mg/kg/day divided BID for 8 weeks
2. Topical corticosteroids:
   - Fluticasone 880-1760 mcg/day for 8 weeks
   - OR Budesonide 2 mg/day for 8 weeks

E. PRURIGO NODULARIS
1. Super-potent topical corticosteroids under occlusion ≥ 4 weeks
2. Systemic options (≥ 12 weeks trial):
   - Gabapentin titrated to ≥ 1800 mg/day
   - Pregabalin ≥ 300 mg/day
   - Cyclosporine 3-5 mg/kg/day
   - Methotrexate 15-25 mg/week

III. CONTRAINDICATIONS & PRECAUTIONS
1. Absolute contraindications:
   - Known hypersensitivity to dupilumab
   - Active helminth infection (must treat first)

2. Relative contraindications requiring specialist input:
   - History of conjunctivitis or keratitis
   - Eosinophil count > 1500 cells/μL (evaluate for HES)
   - Active varicella or herpes zoster

3. Vaccination requirements:
   - Complete age-appropriate vaccines before initiation
   - No live vaccines during treatment

IV. RESPONSE CRITERIA FOR CONTINUATION

A. ATOPIC DERMATITIS
- EASI-50 (50% improvement) by 16 weeks
- OR IGA improvement of ≥ 2 points
- AND Pruritus NRS reduction ≥ 3 points

B. ASTHMA
- 50% reduction in exacerbations
- OR ACQ improvement ≥ 0.5
- OR FEV1 improvement ≥ 100 mL

C. CRSwNP
- NPS reduction ≥ 2 points
- OR SNOT-22 improvement ≥ 8.9 points
- OR Smell identification improvement

D. EoE
- Peak eosinophil count < 15/hpf
- OR DSQ improvement ≥ 30%

E. PRURIGO NODULARIS
- Nodule count reduction ≥ 25%
- AND Pruritus NRS reduction ≥ 4 points

V. SPECIAL POPULATIONS
1. Pregnancy: Category B - use if benefit outweighs risk
2. Elderly: No dose adjustment needed
3. Hepatic/Renal impairment: No dose adjustment
4. Transitioning from other biologics: Washout periods vary